Quote | Viracta Therapeutics Inc. (NASDAQ:VIRX)
Last: | $0.825 |
---|---|
Change Percent: | -1.01% |
Open: | $0.8293 |
Close: | $0.825 |
High: | $0.8392 |
Low: | $0.8076 |
Volume: | 56,518 |
Last Trade Date Time: | 05/09/2024 03:00:00 am |
News | Viracta Therapeutics Inc. (NASDAQ:VIRX)
2024-05-09 17:36:13 ET More on Viracta Therapeutics Day One wins FDA nod for brain cancer therapy, Ojemda Viracta slides on lower response rate in trial for lymphoma treatment cohort Seeking Alpha’s Quant Rating on Viracta Therapeutics Historical earni...
Presented positive topline Nana-val results from Stage 1 of the pivotal Phase 2 NAVAL-1 trial in patients with relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV + ) peripheral T-cell lymphoma (PTCL) Initial results from the ongoing NAVAL-1 trial further validate ...
Message Board Posts | Viracta Therapeutics Inc. (NASDAQ:VIRX)
Subject | By | Source | When |
---|---|---|---|
$VIRX- Took a starter position @ $5.01 today. | AOuvier | investorshub | 11/24/2021 5:53:23 PM |
WOW | TheSilverFox121 | investorshub | 06/25/2021 9:41:45 PM |
Great to see some upwards strength! GLTA | TheSilverFox121 | investorshub | 06/14/2021 3:37:55 PM |
I just bought in at 9.07 GLTA | TheSilverFox121 | investorshub | 03/09/2021 5:11:57 PM |
buy buy buy!!!! | trity | investorshub | 03/01/2021 2:20:51 PM |
News, Short Squeeze, Breakout and More Instantly...
Viracta Therapeutics Inc. Company Name:
VIRX Stock Symbol:
NASDAQ Market:
Presented positive topline Nana-val results from Stage 1 of the pivotal Phase 2 NAVAL-1 trial in patients with relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV + ) peripheral T-cell lymphoma (PTCL) Initial results from the ongoing NAVAL-1 trial further validate ...
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the...
Shares of The Travelers Companies, Inc. (NYSE: TRV) fell sharply during Wednesday’s session following first-quarter earnings. Travelers repo...